Nivolumab vs Peginterferon Alfa-2B
Nivolumab vs Peginterferon Alfa-2B: Overview
This comparison examines the pharmacological differences between Nivolumab and Peginterferon Alfa-2B.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Nivolumab β 27 days.
Chemical Properties
Type: Nivolumab β Antibody; Peginterferon Alfa-2B β Protein.